Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma
Anthony W.H. Chan(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Hidenori Toyoda(Ogaki Municipal Hospital), Charing C. N. Chong(National University of Singapore), Philip J. Johnson(Prince of Wales Hospital), Ka‐Fai To(Chinese University of Hong Kong), Toshifumi Tada(Himeji Red Cross Hospital), Anthony T.�C. Chan(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Takshi Kumada(Ogaki Municipal Hospital), Winnie Yeo(Chinese University of Hong Kong)
Cited by 123
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k